CDT Equity (CDT) Change in Accured Expenses (2022 - 2026)
CDT Equity's (CDT) quarterly Change in Accured Expenses came in at -$434000.0 in Q1 2026, down 309.66% YoY from $207000.0 in Q1 2025, and down 126.61% on a QoQ basis from $1.6 million in Q4 2025.
CDT Equity (CDT) Change in Accured Expenses (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Change in Accured Expenses data on file, last reported at -$434000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 309.66% year-over-year to -$434000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $473000.0 (up 154.24% YoY) and the FY2025 annual result came in at $1.1 million, up 208.16% from the prior year.
- Change in Accured Expenses slipped to -$434000.0 in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.6 million in Q4 2025 to a low of -$743000.0 in Q3 2024.
- A 5-year average of $46764.7 and a median of -$145000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 432.02% — and 2025, when it jumped 953.93%.
- Tracing CDT's Change in Accured Expenses over 5 years: stood at -$496000.0 in 2022, then surged by 128.63% to $142000.0 in 2023, then slumped by 234.51% to -$191000.0 in 2024, then jumped by 953.93% to $1.6 million in 2025, then tumbled by 126.61% to -$434000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$434000.0 (Q1 2026), $1.6 million (Q4 2025), and -$381000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | -12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12,000.00 |
| Jun 30, 2026 | -12,000.00 |
| Mar 31, 2026 | -434,000.00 |
| Mar 31, 2026 | -434,000.00 |
| Dec 31, 2025 | 1.63 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | -381,000.00 |
| Sep 30, 2025 | -381,000.00 |
| Jun 30, 2025 | -343,000.00 |
| Jun 30, 2025 | -343,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | -191,000.00 |
| Dec 31, 2024 | -191,000.00 |
| Sep 30, 2024 | -743,000.00 |
| Sep 30, 2024 | -743,000.00 |
| Jun 30, 2024 | -145,000.00 |
| Jun 30, 2024 | -145,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |